Extended combined screening for preeclampsia prediction in women with diabetes mellitus

Q4 Medicine
R. Kapustin, Elizaveta M. Tcybuk, E. Kopteeva, E. Alekseenkova, S. Chepanov, E. Shelaeva, O. Arzhanova, A. Korenevsky, I. Kogan
{"title":"Extended combined screening for preeclampsia prediction in women with diabetes mellitus","authors":"R. Kapustin, Elizaveta M. Tcybuk, E. Kopteeva, E. Alekseenkova, S. Chepanov, E. Shelaeva, O. Arzhanova, A. Korenevsky, I. Kogan","doi":"10.17816/jowd321321","DOIUrl":null,"url":null,"abstract":"BACKGROUND:Early screening for preeclampsia has shown high efficiency for low-risk groups, however, the presence of systemic vascular disease in patients with diabetes mellitus complicates their use and requires the development of additional approaches to predicting preeclampsia in this group of patients. \nAIM:The aim of this study was to evaluate the effectiveness of early prediction of preeclampsia with extended combined screening in patients with pregestational types of diabetes mellitus. \nMATERIALS AND METHODS:This study included 75 pregnant women: 40 patients with type 1 diabetes mellitus, and 35 patients with type 2 diabetes mellitus. To determine the risk of further preeclampsia development, we evaluated biochemical, biophysical and anamnestic factors, along with the serum levels of placental growth factor, soluble fms-like tyrosine kinase 1, and soluble endoglin at 11+0to 13+6gestational weeks. The main outcome assessed was the development of preeclampsia. \nRESULTS:In patients with further development of preeclampsia (35% in type 1 and 40 % in type 2 diabetic women), we observed higher soluble fms-like tyrosine kinase 1 / placental growth factor ratios, as well as elevated serum soluble endoglin (type 1 diabetes mellitus) and soluble fms-like tyrosine kinase 1 (type 2 diabetes mellitus) levels. Isolated determination of placental growth factor showed no significant differences in the levels of this angiogenic factor in preeclampsia. A multivariate predictive model for preeclampsia demonstrated high prognostic parameters: for patients with type 1 diabetes mellitus, area under the curve was 0.96 (95% confidence interval 0.931.00), with positive predictive value 76.7% and negative predictive value 90.1%; for patients with type 2 diabetes mellitus, area under the curve was 0.94 (95% confidence interval 0.861.00), with positive predictive value 88.5% and negative predictive value 97.1%. \nCONCLUSIONS:Specific biochemical and biophysical markers of preeclampsia combined with maternal risk factors and assessment of carbohydrate metabolism can increase the predictive value of early screening studies for preeclampsia in women with pregestational diabetes mellitus.","PeriodicalId":16623,"journal":{"name":"Journal of obstetrics and women's diseases","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of obstetrics and women's diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17816/jowd321321","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND:Early screening for preeclampsia has shown high efficiency for low-risk groups, however, the presence of systemic vascular disease in patients with diabetes mellitus complicates their use and requires the development of additional approaches to predicting preeclampsia in this group of patients. AIM:The aim of this study was to evaluate the effectiveness of early prediction of preeclampsia with extended combined screening in patients with pregestational types of diabetes mellitus. MATERIALS AND METHODS:This study included 75 pregnant women: 40 patients with type 1 diabetes mellitus, and 35 patients with type 2 diabetes mellitus. To determine the risk of further preeclampsia development, we evaluated biochemical, biophysical and anamnestic factors, along with the serum levels of placental growth factor, soluble fms-like tyrosine kinase 1, and soluble endoglin at 11+0to 13+6gestational weeks. The main outcome assessed was the development of preeclampsia. RESULTS:In patients with further development of preeclampsia (35% in type 1 and 40 % in type 2 diabetic women), we observed higher soluble fms-like tyrosine kinase 1 / placental growth factor ratios, as well as elevated serum soluble endoglin (type 1 diabetes mellitus) and soluble fms-like tyrosine kinase 1 (type 2 diabetes mellitus) levels. Isolated determination of placental growth factor showed no significant differences in the levels of this angiogenic factor in preeclampsia. A multivariate predictive model for preeclampsia demonstrated high prognostic parameters: for patients with type 1 diabetes mellitus, area under the curve was 0.96 (95% confidence interval 0.931.00), with positive predictive value 76.7% and negative predictive value 90.1%; for patients with type 2 diabetes mellitus, area under the curve was 0.94 (95% confidence interval 0.861.00), with positive predictive value 88.5% and negative predictive value 97.1%. CONCLUSIONS:Specific biochemical and biophysical markers of preeclampsia combined with maternal risk factors and assessment of carbohydrate metabolism can increase the predictive value of early screening studies for preeclampsia in women with pregestational diabetes mellitus.
糖尿病女性子痫前期预测的扩展联合筛查
背景:早期子痫前期筛查在低危人群中显示出高效率,然而,糖尿病患者存在全身性血管疾病使筛查的应用复杂化,需要开发更多的方法来预测这组患者的子痫前期。目的:本研究的目的是评估扩展联合筛查早期预测妊娠型糖尿病患者子痫前期的有效性。材料与方法:本研究纳入孕妇75例,1型糖尿病患者40例,2型糖尿病患者35例。为了确定子痫前期进一步发展的风险,我们评估了生化、生物物理和遗忘因素,以及胎盘生长因子、可溶性纤维样酪氨酸激酶1和可溶性内啡肽在妊娠11+0至13+6周的血清水平。评估的主要结果是先兆子痫的发展。结果:在进一步发展为子痫前期的患者中(1型糖尿病女性占35%,2型糖尿病女性占40%),我们观察到更高的可溶性fms样酪氨酸激酶1 /胎盘生长因子比率,以及血清可溶性内激素(1型糖尿病)和可溶性fms样酪氨酸激酶1(2型糖尿病)水平升高。胎盘生长因子的分离测定显示,这种血管生成因子在子痫前期的水平没有显著差异。子痫前期的多因素预测模型具有较高的预后参数:1型糖尿病患者曲线下面积为0.96(95%可信区间0.931.00),阳性预测值为76.7%,阴性预测值为90.1%;2型糖尿病患者曲线下面积为0.94(95%可信区间0.861.00),阳性预测值为88.5%,阴性预测值为97.1%。结论:子痫前期特异性生化和生物物理标志物结合母体危险因素及碳水化合物代谢评估可提高妊娠期糖尿病妇女子痫前期筛查研究的预测价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of obstetrics and women's diseases
Journal of obstetrics and women's diseases Medicine-Obstetrics and Gynecology
CiteScore
0.40
自引率
0.00%
发文量
53
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信